

Systematic review

Detection of cerebral aneurysms using artificial intelligence: a systematic review and meta-analysis

Munaib Din,¹ Siddharth Agarwal,¹ Mariusz Grzeda,¹ David A Wood,¹ Marc Modat,¹ Thomas C Booth ^{1,2}

ABSTRACT

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx. doi.org/10.1136/jnis-2022-019456).

¹School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK ²Department of Neuroradiology,

King's College Hospital NHS Foundation Trust, London, UK

Correspondence to

Dr Thomas C Booth, School of Biomedical Engineering & Imaging Sciences, King's College London, London SE5 9RS, UK; tombooth@doctors.org.uk

Received 29 July 2022 Accepted 11 October 2022 Published Online First 14 November 2022 **Background** Subarachnoid hemorrhage from cerebral aneurysm rupture is a major cause of morbidity and mortality. Early aneurysm identification, aided by automated systems, may improve patient outcomes. Therefore, a systematic review and meta-analysis of the diagnostic accuracy of artificial intelligence (AI) algorithms in detecting cerebral aneurysms using CT, MRI or DSA was performed.

Methods MEDLINE, Embase, Cochrane Library and Web of Science were searched until August 2021. Eligibility criteria included studies using fully automated algorithms to detect cerebral aneurysms using MRI, CT or DSA. Following Preferred Reporting Items for Systematic Reviews and Meta-Analysis: Diagnostic Test Accuracy (PRISMA-DTA), articles were assessed using Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Meta-analysis included a bivariate randomeffect model to determine pooled sensitivity, specificity, and area under the receiver operator characteristic curve (ROC-AUC). PROSPERO: CRD42021278454.

Results 43 studies were included, and 41/43 (95%) were retrospective. 34/43 (79%) used AI as a standalone tool, while 9/43 (21%) used AI assisting a reader. 23/43 (53%) used deep learning. Most studies had high bias risk and applicability concerns, limiting conclusions. Six studies in the standalone AI meta-analysis gave (pooled) 91.2% (95% CI 82.2% to 95.8%) sensitivity; 16.5% (95% CI 9.4% to 27.1%) false-positive rate (1-specificity); 0.936 ROC-AUC. Five reader-assistive AI studies gave (pooled) 90.3% (95% CI 88.0% – 92.2%) sensitivity; 7.9% (95% CI 3.5% to 16.8%) false-positive rate; 0.910 ROC-AUC.

Conclusion AI has the potential to support clinicians in detecting cerebral aneurysms. Interpretation is limited due to high risk of bias and poor generalizability. Multicenter, prospective studies are required to assess AI in clinical practice.

INTRODUCTION

Check for updates

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

To cite: Din M, Agarwal S, Grzeda M, et al. J NeuroIntervent Surg 2023;**15**:262–271.

BMJ

Cerebral aneurysm rupture is the most common cause of non-traumatic subarachnoid hemorrhage, accounting for 85% of cases.¹ Aneurysmal subarachnoid hemorrhage (aSAH) yields a poor prognosis, with a mortality rate of up to 44%.² There is also a large morbidity burden with up to a fifth of surviving patients becoming functionally dependent.²

Aneurysms are common with an estimated prevalence of 3.2% in the general population, but may be higher among females, the elderly, those with

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Aneurysm detection using artificial intelligence (AI) has been described as a primary focus in the field of neurointervention, but there has been no comprehensive systematic review or meta-analysis of relevant studies to assess their suitability for clinical use.

WHAT THIS STUDY ADDS

- \Rightarrow Most studies had a high risk of bias with poor generalizability (only 11/43 studies (26%) used ideal reference standards, and 6/43 studies (14%) used external test sets). AI tools for aneurysm detection are not ready for incorporation into routine clinical practice because of these reasons as well as the low level of evidence supporting their use, and AI performance being compromised by high falsepositive rates: while univariate per-aneurysm analysis of 22 studies gave an 89.0% pooled true-positive rate, the high false-positive rate means that each examination will produce several aneurysm candidates requiring review, plausibly leading to an increase in workload and cost.
- ⇒ Nonetheless, their eventual use in the clinic is possible given that bivariate *per-patient analysis* of six studies using standalone AI, and five studies using reader-assistive AI, gave 0.936 and 0.910 area under the receiver operating characteristic curve, respectively.

HOW THIS STUDY MIGHT AFFECT RESEARCH PRACTICE OR POLICY

⇒ To ensure clinical adoption, large and representative datasets should be used in studies developing AI tools, with subsequent clinical validation achieved through prospective multicenter studies.

a strong family history of aneurysm formation, certain genetic conditions, smokers and those with hypertension.³ The early identification of aneurysms provides the opportunity for expert rupture risk stratification to allow the optimal course of management to be expedited with the aim of improving outcomes.⁴ If optimal management requires treatment, this may be endovascular embolization or surgical clipping.

There are two common indications where the accurate detection of cerebral aneurysms is



required. One is following aSAH, where the ruptured aneurysm needs to be detected. Another is when an unruptured aneurysm is an incidental finding—for example, during vascular imaging following a stroke or transient ischemic attack. Screening may also occur in high-risk populations.

The reference standard imaging modality to detect cerebral aneurysms is digital subtraction angiography (DSA). However, computed tomography angiography (CTA) and magnetic resonance angiography (MRA) are regularly used in clinical practice due to their less invasive nature.⁵ As the global volume of scans performed increases annually, it is becoming increasingly challenging for the radiology community to meet the reporting demand, impacting human factors such as fatigue.⁶ ⁷ Many cerebral aneurysms can be challenging to discern, and many can be time-consuming to identify. Together, these factors can contribute to diagnostic errors. Artificial intelligence (AI) computer-assisted diagnosis (CAD) tools may help tackle these challenges as they have shown promise as diagnostic biomarkers in accurately and efficiently detecting aneurysms using machine learning.⁸ In clinical practice, such decision support software can be standalone (in place of a reader) or be used to assist the reader. While numerous AI CAD tools have been developed, it is currently unclear how well these perform in clinical practice. The aim of this study is to systematically review and perform a meta-analysis of the diagnostic accuracy of AI CAD diagnostic biomarkers in detecting cerebral aneurysms. This will highlight the current developments in the field, help to direct future research and ultimately guide clinical practice.

MATERIALS AND METHODS

This systematic review and meta-analysis are PROSPERO (International prospective register of systematic reviews) registered (CRD42021278454). The review followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis: Diagnostic Test Accuracy (PRISMA-DTA),⁹ informed by Cochrane review methodology regarding developing study inclusion criteria,¹⁰ study search,¹¹ and quality assessment.¹²

Search strategy and selection criteria

A sensitive search with low precision was undertaken comprising subject headings with exploded terms, without language restrictions.¹¹ Search terms were applied to Embase, MEDLINE, Web of Science, and the Cochrane Register to extract original research articles published until August 2021 (online supplemental table S1). The bibliography of all relevant articles was screened to capture additional articles. Pre-prints and non-peer reviewed articles were excluded.

Inclusion criteria

Included studies consisted of primary research studies, employing brain MRA, CTA or DSA datasets, applying automated AI algorithms, and detecting cerebral aneurysms as the target condition.

Exclusion criteria

Excluded studies were those that used other imaging modalities, used no automated algorithm (in the extraction or selection of features, or in classification/regression), without an English language translation,^{13 14} or animal studies.

Index test and reference standard

The index test was the automated AI model detecting cerebral aneurysms. The reference standard was angiography (DSA, CTA or MRA) and the interpretation (report or image re-review; sole or consensus reading). Two individuals (MD and SA, radiologistclinician, 1 and 4 years neuroimaging research experience, respectively) independently performed the literature search and selection.

Data extraction and risk of bias assessment

Study quality, focusing on the risk of bias and concerns regarding applicability, was assessed using Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) methodology¹⁵ tailored to the review question, incorporating items from the Checklist for Artificial Intelligence in Medical Imaging (CLAIM).¹⁶

Data extracted included: patient demographics; eligibility criteria; dataset imaging modality; scanner manufacturer and model; index test AI algorithm; reference standard employed; and information on training and test sets. Test sets were classified as either 'internal' or 'external'. External test sets were acquired from a (geographically) different institution from where the training data were acquired. Internal test sets were acquired from the same institution. Details relating to hold-out and/or cross-validation methodology, as well as temporal splits where the training and test data were collected from separate periods, were captured. Data were also grouped according to whether the decision support software was tested in standalone or reader-assistive mode.

Data synthesis and statistical analysis

Primary outcome measures were AI diagnostic test accuracy metrics. Two units of analysis were used due to the nature of the data: 'per patient' and 'per lesion (aneurysm)'. Based on the published study data, 2×2 confusion matrices were made for hold-out test sets from which the primary diagnostic accuracy measures of sensitivity (recall) and specificity were calculated. Where performance measures for both internal and external tests were available, the external test data were used to determine performance accuracy. Specificity was only derivable from studies that provided per-patient data as the number of true negatives is arbitrary on a per-lesion basis. Therefore, for metaanalysis, the studies were divided into two groups: the first group (A) involved studies with sensitivity and specificity per-patient values; and the second group (B) involved studies with only sensitivity per-lesion values. The area under the receiver operating characteristics curve (ROC-AUC) values and the number of false-positive lesions per patient were extracted where available.

Secondary outcome measures were diagnostic test accuracy metrics of radiologists using AI; therefore 'reader' and 'reader & AI' performance metrics were also obtained. The term 'reader' was applied to any appropriately trained individual interpreting the imaging.

Data were extracted and quality assessment was performed independently by two reviewers (MD and SA). Disagreements were resolved through discussion, with any final arbitration through a third reader (TCB, neuroradiologist, 13 years AI research experience).

Meta-analysis

For group A, the meta-analysis's principal diagnostic accuracy measures were sensitivity and specificity. A bivariate randomeffect model¹⁷ (online supplemental material) was used to determine two pooled primary measures of accuracy: the true-positive rate (sensitivity/recall), and the specificity. Parameters of the bivariate random-effect model also allowed for the estimation of the summary ROC (SROC) curve and the SROC-AUC. Using a resampling approach¹⁸ model, estimates were used to obtain the



Figure 1 Flow diagram for systematic review and meta-analysis of cerebral aneurysm detection using artificial intelligence.

pooled measures of balanced accuracy, the positive and negative likelihood ratios, and the diagnostic odds ratio.

Studies in group B underwent a univariate meta-analysis because they only contained data for sensitivity metrics. As all outcome measures included in this group were originally expressed as proportions of true-positives (sensitivities), the key results of meta-analysis (summary effect sizes) were also reported as pooled proportions.

Both group analyses used a linear random-effect model taking into account the possible true heterogeneity of effects across studies.¹⁹ The meta-analysis was conducted by a statistician (MG, 15 years of relevant experience). All the statistical analyses were performed in R (v 3.6.1). The R Package Mada (v 0.5.10)²⁰ was used for the bivariate model.

RESULTS

Characteristics of included studies and bias assessment

Figure 1 shows that overall, 1736 studies met the search criteria and 99 potentially eligible full-text articles were assessed. Forty-three studies ranging from October 2004 to August 2021 were included.²¹⁻⁶³ The total number of patient cases used for both

training and testing was 18143, and of these 10625 patients had aneurysms, with a combined total of 12990 aneurysms (datasets that were used across different studies were only included once). Tables 1 and 2 detail the study characteristics and are presented as subgroups containing 34/43 (79%) 'AI standalone' and 9/43 (21%) 'AI & reader' studies, respectively. One 'AI standalone' study (1/34, 3%) was prospective. One 'AI & reader' study (1/9, 11%) was prospective and used AI CAD during clinical practice. The remaining studies (41/43, 95%) in both subgroups were conducted retrospectively, in a laboratory environment, thus providing limited evidence on its clinical validity.⁶⁴ Eleven studies employed DSA (11/43, 26%), 6/43 (14%) CTA, 24/43 (56%) MRA, and 2/43 (5%) multi-modality datasets. There were 13/43 (30%) multicenter studies (dataset from two or more different sites). Twenty-six studies (26/43, 60%) used more than one scanner model, and 13/43 (30%) studies used scanners from more than one manufacturer. Nineteen studies (19/43, 44%) included only datasets where patients had aneurysms.

Table 1 Studies applying artificial intelligence as a standalone method for the automatic detection of cerebral aneurysms

Author	Modality	Study design	Demographics: total cases; aneurysm-positive cases (+); total aneurysms (A). If data available: % female; mean age; mean aneurysm diameter (range); rupture status	Reference standard	Index test	Dataset: number of cases (number of which contain aneurysms (+), if different from the total number of cases)	Type of test set	Test set performance(If available): lesion sensitivity; FP/case; PPV; NPV; accuracy; patient sensitivity; patient specificity; precision; AUC; F1 score
Nomura et al 2014 ²¹	MRA-TOF	Retrospective	2269 cases; 472+; 578A; 3 mm	2 radiologists	cCAD: Gaussian filter with	Training=490 (362+); Test=1779 (110+)	Internal; temporal split	Lesion sensitivity: 95.2%;
Jin <i>et al</i> 2016 ²²	MRA-TOF	Retrospective single center	30 cases; 30+; 31A; 69.2 years; 67% female; 3.7 mm (2.0–5.5 mm); unruptured	2 neuroradiologists reviewed CTA/DSA	cCAD: ellipsoid convex enhancement filter	Test=30	Internal; LOOCV	Lesion sensitivity: 100%; FP/ case: 31.8
Arimura et al 2006 ²³	MRA-TOF	Retrospective multicenter	178 cases; 87+; 214A; 5.2 mm (1–15 mm); unruptured	2 neuroradiologists reviewed MRA-TOF and other available imaging	cCAD: 3D selective enhancement filter using Hessian matrix, shape-based difference image technique	Training=115 (53+); Training/ test=63 (34+)	Internal; LOOCV	Lesion sensitivity: 94%;, FP/ case: 2.3
Arimura et al 2004 ²⁴	MRA-TOF	Retrospective single center	60 cases; 29+; 36A; 6.6 mm (3–26 mm); unruptured	NR	cCAD: 3D selective enhancement filter using Hessian matrix	Test=60 (29+)	Internal; LOOCV	Lesion sensitivity: 100%; FP/ case: 2.4
Joo <i>et al</i> 2020 ²⁵	MRA-TOF	Retrospective multicenter	744 cases; 644+; 761A; 3.2 mm; unruptured	2 neuroradiologists reviewed MRA-TOF	DL: 3D ResNet	Training and validation=468; Internal test=170 (120+). External test106 (56+)	External; geographical split	Lesion sensitivity: 85.7%; PPV: 91.5%; Accuracy: 88.5%; Patient specificity: 98.0%
Yang <i>et al</i> 2011 ²⁶	MRA-TOF	Retrospective single center	287 cases; 92+cases; 147A; (1–31 mm); unruptured	1 general and 1 neuroradiologist reviewed DSA	cCAD: Dot enhancement filter	Test=92 (92+)	No training required	Lesion sensitivity: 96%; FP/ case: 11.6
Timmins et al 2021 ²⁷	MRA-TOF	Retrospective single center	300 cases; 254+; 282A; 75% female; 55 years; 3.6 mm (1.0–15.9 mm); unruptured	1 neuroradiologist and 1 trained reader reviewed MRA-TOF	DL: 3D CNN Retina U-net by MiBaumgartner	Training=113 cases (93+); Test=141 (115+)	Internal; hold out	Lesion sensitivity: 67%; FP/ case: 0.13
Nakao <i>et al</i> 2018 ²⁸	MRA-TOF	Retrospective single center	450 cases; 450+; 508A; 45% female; 61 years; 3 mm; unruptured	2 radiologists reviewed MRA-TOF	DL: Voxel based CNN (chainer 1.6.1)	Training=300; Validation=50; Test=100	Internal; temporal split	Lesion sensitivity: 94.2%; FP/ case: 2.9
Hanaoka <i>et al</i> 2019 ²⁹	MRA-TOF	Retrospective single center	300 cases; 300+; 300A	2 radiologists reviewed MRA-TOF	cCAD: HoTPiG (voxel-based feature set) and Hessian based features with single SVM	Training=200; Test=100	Internal; 3- fold CV	Lesion sensitivity: 80%; FP/ case: 3
Faron <i>et al</i> 2020 ³⁰	MRA-TOF	Retrospective multicenter	85 cases; 85+; 115A; 68% female; 56 years; 7.1 mm (2.1–37 mm); unruptured	1 neuroradiologist reviewed MRA-TOF and other available imaging	DL: DeepMedic CNN	Training=58; Validation=10; Test=17	Internal; CV (5-fold)	Lesion sensitivity: 90%; FP/ case: 6.1
Sichtermann <i>et al</i> 2019 ³¹	MRA-TOF	Retrospective multicenter	85 cases; 85+; 115A; 68% female; 56 years; 7.1 mm (2.1–37 mm); unruptured	2 radiologists reviewed MRA-TOF and other available imaging	DL: DeepMedic CNN	Training=58; Validation=10; Test=17	Internal; CV (5-fold)	Lesion sensitivity: 90%; FP/ case: 6.1
Hou <i>et al</i> 2020 ³²	MRA-TOF	Retrospective multicenter	350 cases; 179+; 179A, 7.5 mm (2.4–23 mm); unruptured	NR	DL: 1D CNN by generating 1D vectors from MIP images	Training=245 (126+); Validation=35 (17+); Test=70 (36+)	Internal; hold out	Lesion sensitivity: 93.2%; Precision: 96.9%; Accuracy: 95.2%; AUC: 0.99;F1: 0.950
Allenby et al 2021 ³³	MRA-TOF	Retrospective multicenter	623 cases; 21+; 21A; unruptured	1 interventional radiologist reviewed MRA-TOF	cCAD: single-voxel morphometry	Test=623 (21+)	No training required	Patient specificity: 86%; Sensitivity: 81%; FP/case: 0.14
Stember et al 2019 ³⁴	MRA-TOF	Retrospective single center	336 cases; 336+; 336A; (3–23 mm)	Original radiological reports	DL: U-net CNN	Training=250; Test=86	Internal; hold out	Lesion sensitivity: 98.8%; AUC:0.87
Chen <i>et al</i> 2020 ³⁵	MRA-TOF	Retrospective single center	131 cases; 131+; 140A, 63% female; 57 years; 6.5 mm; unruptured	2 radiologists reviewed DSA	DL: 3D-U-net CNN	Training=76; Validation=20; Test=35	Internal; hold out	Lesion sensitivity: 82.9%; FP/ case: 0.86
Ueda <i>et al</i> 2019 ³⁶	MRA-TOF	Retrospective multicenter	1271 cases; 1271+; 1477A; 72% female; 68 years; 4.1 mm	2 radiologists reviewed MRA-TOF	DL: ResNet-18 using skip connections	Training and validation=683; Internal test=521; External test=67	External; geographical split	Lesion sensitivity: 93%; FP/ case: 5
Nomura et al 2021 ³⁷	MRA-TOF	Retrospective multicenter	519 cases; 399+; 448A; 46% female; 3.1 mm	2 radiologists reviewed MRA-TOF	DL/cCAD: 3 software: (i) 3D local intensity structure analysis; (ii) graph-based; (iii) CNN	Training=399 (339+); Test set 1=60 (30+); Test set 2=60 (30+)	External; geographical split	Per patient or per lesion performance measurements not available
Nemoto et al 2017 ³⁸	MRA-TOF	Retrospective single center	300 cases; 300+; 300A; 50% female; 59.8 years; 3.1 mm	2 radiologists reviewed MRA-TOF	cCAD: voxel and candidate classifier ensembles with cost-sensitive AdaBoost	Training=200; Test=100	Internal; 3- fold CV	Lesion sensitivity: 56.8%; FP/case: 10
Hainc <i>et al</i> 2020 ³⁹	2D DSA	Retrospective single center	240 cases; 136+; 186A; 65% female, 59 years, 7 mm; ruptured and unruptured	2 neuro- interventional radiologists reviewed DSA	DL: commercial software by Cognex, ViDi Suite 2.0, Cognex Inc	Split via DSA Projections: 706 (335+) Training=565; Test=141	Internal; 45- fold CV	Lesion sensitivity: 79%; Specificity: 79%;F1: 0.77; Precision: 0.75; Mean AUC: 0.76
Zeng <i>et al</i> 2020 ⁴⁰	2D DSA	Retrospective single center	300 cases; 250+; 263A	5 radiologists reviewed DSA	DL: 2D CNN with spatial information fusion (VGG16)	No test set	No separate test set	No test set data
Jin <i>et al</i> 2020 ⁴¹	2D DSA	Retrospective single center	493 cases; 493+; 1205A; 62% female; 55 years; 7.4 mm (1.3–40 mm)	2 neurologists reviewed DSA and third reader for arbitration	DL: end to end spatial temporal U-Net CNN (Keras-2.2.0 with TensorFlow-1.4.0 backend)	Training=249; Validation=98; Test=146	Internal; hold out	Lesion sensitivity: 89.3%; Patient sensitivity: 97.7%; FP/case: 3.77
Liu <i>et al</i> 2021 ⁴²	3D DSA	Retrospective single center	451 cases; 451+; 485A; 61% female; 56 years; 7.1 mm	2 neuroradiologists reviewed DSA	DL: 3D-Dense-Unet CNN	Training=347; Validation=41; Test=63	Internal; hold out	Lesion sensitivity: 88.4%; FP/ case: 0.61
Hu <i>et al</i> 2020 ⁴³	3D DSA	Retrospective single center	145 cases; 145+; 165A; 66% female; 57.8 years	2 neuroradiologists reviewed DSA	cCAD: Bayesian optimized Hessian matrix filter	Test=145	No training required	Lesion sensitivity: 96.4%; Precision: 0.946; AUC: 0.98; F1 score: 0.955
Duan <i>et al</i> 2019 ⁴⁴	2D DSA	Prospective single center	281 cases; 261+; 261A; 85% female; ruptured and unruptured	2 radiologists reviewed DSA	DL: CNN based on feature pyramid networks (using ResNet50)	Training=241; Test=40 (20+)	Internal; temporal split	Patient sensitivity: 96.0%, Specificity: 91.0%; Accuracy: 93.5%; AUC: 0.94; F1 score: 0.94
								Continued

Table 1 Continued

Author	Modality	Study design	Demographics: total cases; aneurysm-positive cases (+); total aneurysms (A). If data available: % female; mean age; mean aneurysm diameter (range); rupture status	Reference standard	Index test	Dataset: number of cases (number of which contain aneurysms (+), if different from the total number of cases)	Type of test set	Test set performance(If available): lesion sensitivity; FP/case; PPV; NPV; accuracy; patient sensitivity; patient specificity; precision; AUC; F1 score
Rahmany <i>et al</i> 2018 ⁴⁵	2D DSA	Retrospective single center	30 cases; 30+; 30A	2 neuroradiologists reviewed DSA	cCAD: Priori knowledge applied to fuzzy logic-based model with Fuzzy information fusion	Test=30	No training required	Results for 5 cases : Patient sensitivity: 100%; Specificity: 100%, Accuracy: 98.4%; AUC: 0.96
Rahmany <i>et al</i> 2019 ⁴⁶	2D DSA	Retrospective single center	30 cases; 30+; 30A	2 neuroradiologists reviewed DSA	cCAD: LBP for feature extraction, and KNN classification	Training=20; Test=10	Internal; hold out	Per patient or per lesion performance metrics not available
Malik <i>et al</i> 2018 ⁴⁷	DSA	Retrospective single center	59 cases; 47+; 47A; (6–21 mm); unruptured	1 radiologist reviewed DSA	DL: classification multi-layer perceptron neural network	Split into 210 ROI: Training=189; Test=21	Internal; 10- fold CV	Per patient or per lesion performance metrics not available
Chandra <i>et al</i> 2017 ⁴⁸	2D DSA	Retrospective single center	15 cases; 15+; 15A	NR	cCAD: iterative double automated thresholding, morphological filtering	Test=15	No training required	Per patient or per lesion performance metrics not available
Khan <i>et al</i> 2019 ⁴⁹	DSA	Retrospective single center	4 cases; 4+; 4A	NR	cCAD: sub-band morphological operation, gaussian filtering	Test=4	No training required	Per patient or per lesion performance metrics not available
Shi <i>et al</i> 2020 ⁵⁰	СТА	Retrospective multicenter	1388 cases; 908+; 1145A; 31.3% female; 64 years; 4.4 mm; ruptured and unruptured	3 neuroradiologists reviewed DSA	DL: end-to-end 3D CNN (DAResUNet)	Training=927 (744+); Validation=100 (50+); Testing: internal=150 (75+); external=211 (39+)	External; geographical split	Lesion sensitivity: 76.1%; PPV: 49.3%; NPV: 95.8%; Accuracy: 81.0%; Patient sensitivity: 84.6%; Specificity: 80.2%; FP/ case: 0.27
Shahzad <i>et al</i> 2020 ⁵¹	CTA	Retrospective single center	253 cases; 253+; 294A; 67% female; 55.1 years; ruptured and unruptured	1 neurosurgeon and 1 radiologist reviewed CTA and DSA (if available)	DL: 3D CNN based on DeepMedic	Training=68 (79+); Test=185 (215)	Internal; temporal split	Lesion sensitivity: 82%; F1: 0.66; Precision: 0.54; FP/ case: 0.81
Dai <i>et al</i> 2020 ⁵²	CTA	Retrospective multicenter	311 cases; 311+; 344A; 5.4 mm (1–24 mm)	1 radiologist reviewed CTA	DL: RCNN model and Resnet-50	Training=208; Test=103	Internal; hold out	Lesion sensitivity: 91.8%; FP/ case 8.9
Hentschke <i>et al</i> 2014 ⁵³	CE/TOF-MRA /CTA	Retrospective single center	151 cases; 81+; 112A; (2.0–5.5 mm); CTA: 72; CE-MRA: 38; TOF-MRA: 41; unruptured	2 neuroradiologists reviewed imaging	cCAD: sphere-enhancing filter and linear or non-linear classification	Test=151 (81+)	Internal; 4- fold CV	Lesion sensitivity: CE-MRA: 91%; TOF-MRA: 84%; CTA: 69%; FP/case: 10
Lauric <i>et al</i> 2010 ⁵⁴	3D-RA/CTA	Retrospective single center	20 cases; 19+; 20A; (3.2–10 mm); 3D-RA: 10; CTA:10	2 readers reviewed DSA/CT	cCAD: 3D shape analysis using writhe number	Test=20 (19+)	No training required	Lesion sensitivity: DSA: 100%; CTA: 100%; FP/case: DSA: 0.66; CTA: 5.36
				1 1				

+, aneurysm-positive cases; A, aneurysm; AUC, area-under-curve; cCAD, conventional computer assisted diagnosis; CE, contrast enhanced ; CNN, convolutional neural network; CTA, CT angiography; CV, cross-validation; 1D, one dimensional; 2D, two dimensional; 3D, three dimensional; DL, deep learning; 3D-RA, three dimensional rotational angiography; DSA, digital subtraction angiography; FP(case, false-positives per case; HoTPiG, histogram of triangular paths in graph; KNN, k-nearest neighbour; LBP, local binary patterns; LOO, leave-one-out; MIP, maximum intensity projection; ML, machine learning; MRA-TOF, MR angiography-time of flight; NPV, negative predictive value; NR, not recorded; PPV, positive predictive value; ROI, regions of interest; SVM, support vector machine.

Reference standards

In 13/43 (30%) studies, the reference standard imaging modality of DSA imaging was used. The remainder used either MRA, CTA or a combination of imaging modalities. At least two independent readers were employed to determine the reference standard in 29/43 (67%) studies. The remainder used one reader or solely based the reference standard on the initial radiological reports.

Algorithm

Approximately half the studies (23/43, 53%) used a deep learning (DL) methodology, particularly convolutional neural networks (CNNs). The remainder used CAD systems employing shape filters and/or classic machine learning techniques.

Test sets

Six studies (6/43, 14%) used an external test set. Nineteen studies (19/43, 44%) used an internal hold-out test set, of which 8/43 (19%) studies employed a temporal split. Cross-validation (CV) alone was performed in 10/43 (23%) studies. One study did not have a test set, nor did it undergo cross-validation. The remaining 7/43 (16%) studies did not use training data because they used mathematical models utilizing filters for their algorithm.

Al standalone (subgroup)

For those studies (25/34, 74%) which gave results using perlesion analysis, lesion sensitivities ranged from 0.67 to 1.0. Where available, the number of false-positive lesions per scan ranged from 0.13 to 31.8. Results from 6/34 (18%) studies were not comparable as five did not provide performance metrics on a per-patient or per lesion basis, and one did not use a test set.

AI & reader (subgroup)

Per-patient sensitivity and specificity were reported in 5/9 (56%) studies using a mean of the performance of the participating radiologists, with and without AI CAD assistance. These studies showed that there was an improved sensitivity when the imaging was interpreted with AI CAD assistance.

The proposed position of the AI CAD in the clinical pipeline varied among the nine studies. Five of nine studies (56%) placed the AI CAD as a 'second reader' which means that the radiologist initially reviewed the imaging without assistance, and then used the AI CAD to highlight lesion candidates. Conversely, 2/9 (22%) studies placed the AI CAD as a 'first reader', which means that the AI CAD had already highlighted the suspected lesion candidates on the images before the radiologist interpretation. The remaining 2/9 (22%) studies were unclear regarding the position of the AI CAD in the clinical pipeline.

Bias assessment and concerns regarding applicability

An analysis of the risk of bias assessment and concerns regarding applicability was performed for each study and summarized (online supplemental figure 1). Notably, there was a high risk of bias relating to the index test in 74% (32/43) of studies, mainly due to validation design, and 65% (28/43) for the reference standard, largely due to reader strategy and modality used. Regarding concerns of study applicability, these were high or unclear in

Table 2 Studie	s applying ar	rtificial intelligence as a rea	ader-aid for the	detection of cere	bral aneurysms						
Author	Modality	Demographics: total cases; aneurysm-positive cases (+); total aneurysms (A). If data available: %female; mean age; mean aneurysm diameter (range); rupture status	Study design	Dataset: number of cases (number of which contain aneurysms (+), if different from the total number of cases)	Reference	Index test used	Type of test set	Al performance: if available: lesion sensitivity; FP/case; accuracy; patient sensitivity; patient specificity; AUC	Reader performance: If available: lesion sensitivity; FP/case; accuracy; patient sensitivity; patient specificity; AUC	Reader+Al performance: If available: lesion sensitivity; FP/case; accuracy; patient sensitivity; patient specificity; AUC	Position of Al in pipeline
Miki <i>et al</i> 2016 ⁵⁵	MRA-TOF	2701 cases; 189+; 203A; 38% female; 54 years (median)	Prospective single center	Test=2701 (189+)	2 radiologists reviewed MRA, with CAD assistance	cCAD: Gaussian filter based on Nomra <i>et al</i> 2014 ²⁴ (see table 1)	Internal; temporal split	Lesion sensitivity: 82%	Lesion sensitivity: 64%	Lesion sensitivity: 69%	2nd reader
Štepán-Buksakowska <i>e</i> <i>al</i> 2014 ⁵⁶	t MRA-TOF	48 cases; 9+; 11A; 3.1 mm	Retrospective multicenter	Test=48 (9+)	2 neuroradiologists reviewed MRA-TOF and DSA	cCAD: Dot enhancement filter based on Yang <i>et al</i> 2011 ²⁶ (see table 1)	External; Geographical split	Lesion sensitivity: 91 %	Patient sensitivity: 70.4%; specificity: 79.5%; accuracy: 77.8%; AUC: 0.66	Patient sensitivity: 83.4%; patient specificity: 75.7%; accuracy: 77.1%; AUC: 0.76	1st reader
Miki e <i>t al</i> 2020 ⁵⁷	MRA-TOF	250 cases; 100+; 104A; unruptured	Retrospective single center	Test=250 (100+)	2 radiologists reviewed MRA-TOF	DL: Voxel based CNN based on Nakao <i>et al</i> 2018 ²⁸ (see table 1)	Internal; hold out	Lesion sensitivity: 92.3%	NR	Lesion sensitivity: 71%; lesion specificity: 92%; AUC 0.89	Unclear
Kakeda <i>et al</i> 2008 ⁵⁸	MRA-TOF	50 cases; 16+; 16A; 54% female, 64 years; 6.6mm (3–26mm); unruptured	Retrospective multicenter	Test=50 (16+)	2 neuroradiologists reviewed MRA and other available imaging	cCAD: 3D selective enhancement filter using Hessian matrix based on Arimura <i>et</i> al 200623 (see table 1)	Internal; LOOCV	Lesion sensitivity: 81 % FP/case: 2.7	Patient sensitivity: 75.8%; patient specificity: 82.7%; AUC: 0.85	Patient sensitivity: 80.9%; patient specificity: 88.6%; AUC: 0.90	2nd reader
Hirai <i>et al</i> 2005 ⁵⁹	MRA-TOF	50 cases; 22+r, 68% female; 59 years; 7.1 mm (3–26 mm); unruptured	Retrospective single center	Test=50 (22+)	2 neuroradiologists reviewed MRA and other available imaging	cCAD: 3D selective enhancement filter using Hessian matrix based on Arimura <i>et</i> <i>al</i> 2004 ²¹ (see table 1)	Internal; temporal split	NN	AUC: 0.93	AUC: 0.98	2nd reader
Sohn <i>et al</i> 2021 ⁶⁰	MRA-TOF	332 cases; 135+; 169A; 64% female, 62 years; 4mm (2–17mm); unruptured	Retrospective single center	Test=332 (135+)	3 neuroradiologists reviewed MRA other available imaging	DL: 3D ResNet based on Joo <i>et</i> <i>al</i> 2020 ³⁵ (see table 1)	Internal; temporal split	Lesion sensitivity: 92.3%. FP/case: 0.12; patient sensitivity: 74.8%; specificity: 93.9%	Lesion sensitivity: 74.8%; patient sensitivity: 73.5%; patient specificity: 94.8%	Lesion sensitivity 95.0%; patient sensitivity: 86.5%; patient specificity 95.2%	2nd reader
Park <i>et al</i> 2019 ⁶¹	CTA	818 cases; 328+; 358A; 64% female; 58 years; unruptured	Retrospective single center	Training=611 (223+); Validation=92 (46+); Test=115 cases (56+)	1 neuroradiologist reviewed CTA and DSA (if available)	DL: 3D CNN HeadXNet	Internal; hold out	Patient sensitivity: 94.9%; patient specificity: 66.1%; accuracy: 80.9%	Patient sensitivity: 83.1%; specificity: 96.0%; accuracy: 89.3%	Patient sensitivity: 89.0%; patient specificity: 97.5%; accuracy: 93.2%	1st reader
Pennig <i>et al</i> 2021 ⁶²	CTA	172 cases; 172+; 2054; 63% female; 55.4 years; ruptured and unruptured	Retrospective single center	Training and validation=68; Test=104	1 neurosurgeon and 1 radiologist reviewed CTA and DSA (if available)	DL: ensemble model based on Shahzad <i>et</i> <i>al</i> 2020 ⁵¹ (see table 1)	Internal; temporally distinct	Lesion sensitivity: 85.7%; FP/case: 0.84	Lesion sensitivity: 88.1%	Lesion sensitivity: 97.1%	2nd reader
Yang <i>et al</i> 2021 ⁶³	CTA	1468 cases; 1256+; 1543A; 48% female; 57 years; 4.1 mm (1– 22 mm); ruptured and unruptured	Retrospective multicenter	Training=534; Validation=534; Test=400 (188+)	2 radiologists reviewed CTA	DL: 3D CNN ResNet-18	Internal; temporally distinct	Lesion sensitivity: 97.5% FP/case: 13.8 (internal validation set)	Lesion sensitivity: 79.1%; patient sensitivity: 81.6%; specificity: 95.9%; AUC: 0.60	Lesion sensitivity: 88.9%; patient sensitivity: 91.9%; specificity: 90.9%; AUC: 0.61	Unclear
+, aneurysm-positive ca: MR angiography-time of	es; A, aneurysm; A. flight; NR, not reco	l, artificial intelligence; AUC, area-unde orded.	r-curve; CTA, CT angiog	raphy; CV, cross-validatio	n; 2D, two dimensional; 3	D, three dimensional; D	L, deep learning; DS/	۰, digital subtraction angiograp	hy; FP/case, false-positive	es per case; LOO, leave-on	e-out; MRA-TOF,





Figure 2 Forest plots of sensitivity and specificity of detection of cerebral aneurysms using artificial intelligence (AI). (A) AI standalone subgroup. (B) AI & reader subgroup.

95% (41/43) of studies for patient selection. Six studies (6/43, 14%) did not explicitly mention their inclusion or exclusion criteria, and 22/43 (51%) studies excluded patients based on factors that could increase selection bias, such as aneurysm size, type, location, or presence of comorbidities.

Temporal analysis

The studies were divided into two groups depending on the year of publication. The first group consists of 13 studies that were published before 2018 (pre-2018), and the second group consists of 30 studies that were published in 2018 or later (post-2018). This arbitrary cut-off was chosen as it mirrors the notable observation that in 2018, arXiv (a repository where computer science papers are self-archived before publication in a peer reviewed journal) surpassed 100 new machine learning pre-prints per day.^{65 66} In the pre-2018 group, the lesion sensitivities ranged from 56.8% to 100% with false-positives/case ranging from 2.3 to 31.8. Whereas in the post-2018 group, the lesion sensitivities range from 67% to 100%, with a false-positives/case ranging from 0.12 to 13.8. While there is an impression of a slightly lower

false-positive rate in more recent studies, comparison is limited as both groups have a similar high degree of bias and concerns regarding applicability (online supplemental figures 2 and 3). For example, 77% of pre-2018 studies had a high or unclear risk of bias for the index test used, compared with 73% for post-2018 studies; and 69% of pre-2018 and 60% of post-2018 studies had a high or unclear risk of bias for patient selection.

Results of meta-analysis

Group A consisted of 9/43 (21%) studies that were eligible for inclusion in a meta-analysis of per-patient diagnostic accuracy. These were divided into two subgroups: 'AI standalone' (6/9, 67% studies) and 'AI & reader' (5/9, 56% studies). Two studies (2/9, 22%) were included in both subgroups as they provided performance metrics for both categories. Forest plots of sensitivity and specificity (figure 2) graphically showed a high degree of heterogeneity. Additionally, χ^2 tests were applied separately to both primary measures to statisically verify this hypothesis. For the 'AI standalone' subgroup, the P values were <0.001 for both sensitivities and specificities.



SROC curve for diagnostic measures



Figure 3 Summary receiver operator characteristic curve (SROC) for detection of cerebral aneurysms using artificial intelligence (AI). (A) AI stand-alone subgroup. (B) AI & reader subgroup. The summary point estimate and surrounding 95% confidence region is shown.

For the 'AI & reader' subgroup, the P values were 0.43 and <0.001 respectively. Therefore, the bivariate randomeffect model was ideal given the large level of heterogeneity between studies. For the 'AI standalone' subgroup, the pooled true-positive rate (sensitivity) was 91.2% (95% CI 82.2%to 95.8%) and the pooled false-positive rate (1-specificity) was 16.5% (95% CI 9.4% to 27.1%). For the 'AI & reader' subgroup, the pooled true-positive rate was 90.3% (95% CI 88.0% to 92.2%) and the pooled false-positive rate was 7.9%(95% CI 3.5% to 16.8%). A scatter plot of false-positive rates and true-positive rates (figure 3) demonstrates individual ROC point estimates and a summary ROC (SROC) giving an AUC of 0.936 and 0.910 for 'AI standalone' and 'AI & reader' studies, respectively.

Group B included 22/43 (51%) studies that underwent univariate analysis of their per-lesion sensitivity metrics. The

forest plot (figure 4) shows a high degree of heterogeneity, with an I² of 87%. The χ^2 test gave a P value <0.01. The pooled true-positive rate was 89% (95% CI 85% to 92%).

DISCUSSION

Summary of findings

Current evidence for determining the diagnostic accuracy of AI in detecting cerebral aneurysms is of relatively low level.⁶⁷ The validity of diagnostic accuracy is limited due to a high risk of bias and concerns regarding applicability across several domains; approximately half of studies had selective eligibility criteria that excluded patients based on aneurysm morphology or clinical characteristics, and few studies used an external test set while assessing the index test. Approximately half the studies employed DL methodology including CNNs as index tests.

Limitations

Studies assessed

Most studies employed retrospective, single-center, and casecontrol designs using relatively small and enriched samples. Eligibility criteria varied among studies. Some excluded patients with aneurysms of a certain type, size, or other comorbidities. Several studies only included patients who had aneurysms, with no normal participants. These patient selection factors lead to spectrum bias⁶⁸ and limit the generalizability of the results to a real clinical environment.

There were also limitations regarding index test evaluation. Most studies used internal hold-out test sets, often without temporal separation, or cross-validation to evaluate their model, as opposed to external test sets which provide a more accurate indication of how the model generalizes to other hospitals.^{69 70} Furthermore, it was unclear in most studies whether data leakage was prevented at the patient level from follow-up imaging.

Fewer than a third of studies used DSA as their reference standard, considered the ideal reference standard imaging modality for aneurysm detection.⁵ MRA and CTA were used as reference standards in the remainder of the studies, potentially leading to a systematic error with overestimation of model performance, given that it is plausible that not all aneurysms were identified. However, in routine clinical practice cross-sectional angiography is an acceptable first-line diagnostic biomarker because it is noninvasive with good accuracy. Therefore, an AI CAD index test benchmarked against a cross-sectional angiography reference standard demonstrating high-performance accuracy may have clinical applicability, provided that there is adherence to other aspects of reference standard methodology, including using at least two readers.

Another consideration is whether aneurysm rupture status impacts the diagnostic accuracy of AI CAD models including the interaction of aSAH on AI standalone and AI reader assist results. Unfortunately, not all studies mentioned rupture status (17/34 (50%) in AI standalone; 7/9 (78%) in AI reader assist), few contain ruptured aneurysms (4/34 (12%) in AI standalone; 2/9 (22%) in AI reader assist), and fewer still published detailed data precluding a meaningful analysis in this systematic review. For now, there are limited data. One study tested their AI model exclusively on ruptured cerebral aneurysms and found their accuracy to be comparable to other models which used only unruptured cerebral aneurysms.⁵¹ A follow-on study investigated the performance of the same model as a reader aid in aSAH cases and concluded the same.⁶² A third study also found no significant difference in their standalone model's performance in cases



Figure 4 Forest plot of sensitivity for detecting intracranial aneurysms using a per-lesion analysis.

with and without aSAH.⁵⁰ Where possible, future studies should provide a comparison of their model's performance on both ruptured and unruptured cerebral aneurysms. However, regardless of diagnostic accuracy, definitive DSA in almost any case of spontaneous subarachnoid hemorrhage is mandated, AI CAD or not.⁷¹

Review process

Reference standard heterogeneity was also introduced with variable levels of expertise among readers and different labelling methodologies, ranging from using the original radiological report alone to several dedicated radiologists re-reviewing the imaging.

The exclusion of pre-prints may exacerbate publication bias. More data science-oriented teams may be less inclined to publish in a peer reviewed journal compared with more clinically-oriented teams, due to the mismatch between the speed of data science development and the peer review process.⁶⁶

Our review includes studies which range across a large time period. AI methodology is changing at a rapid pace, and it could be argued that the older studies may not accurately reflect the diagnostic performance or quality of the more recent studies. Therefore, this could be a contributing factor to the heterogeneity in the analysis. However, on comparing the newer (post-2018) studies with older (pre-2018) studies, there is no demonstrable improvement in the study quality, with high levels of bias being present in both groups. Even though some recent studies may demonstrate better performance accuracy, the studies themselves are of insufficient quality. This emphasizes the importance for researchers to ensure that they are designing robust, high-quality studies when developing and validating their AI tools.

Role in clinical pipeline

Based on current evidence, AI CAD are unlikely to be used as standalone readers and are more likely to assist radiologists

during diagnosis. One key reason is their high false-positive rate, meaning that each examination will produce several aneurysm candidates requiring review, plausibly leading to an increase in workload and cost. This may make AI CAD systems less appealing to clinicians and healthcare systems.

Studies investigating the impact of AI CAD assisting radiologists implemented the tool in different parts of the clinical pipeline, but numbers were small precluding meaningful analysis. Studies directly investigating pipeline positioning are warranted, incorporating phenomena related to over-reliance of automation⁷² and error associated with 'satisfaction of search'.⁷³⁻⁷⁵ Incremental benefit may be marked when radiologists are interpreting vascular imaging for indications typically unrelated to aneurysms (e.g., ischemic stroke) in centers without neuroradiologists.

Current evidence in the field

Aneurysm detection has been described as a primary focus in the field of cerebral aneurysms and radiology.⁷⁶ Our systematic review and meta-analysis provide evidence for the quality and performance accuracy of all published studies using AI CAD for aneurysm detection. Another recent systematic review and meta-analysis included 20 CNN studies to identify cerebral aneurysms.⁷⁷ Our systematic review emphasizes the current low level of evidence which undermines the performance accuracy of reported studies including those using CNNs, whereas the review by Abdollahifard et al does not raise any concerns regarding the bias or applicability of the studies. The discrepancy is potentially because we systematically applied PRISMA-DTA and QUADAS-2 methodology, which is the standard used for diagnostic accuracy studies.¹⁵ We pooled primary measures of accuracy using bivariate random-effects methodology which accounts for the negative correlation of sensitivity and specificity and differing cut-off values between studies, and second, it accounts for a relatively high degree of heterogeneity in the results of diagnostic studies (online supplemental material). Despite the authors not

performing such an analysis, they conclude that CNN models would be best placed to assist readers rather than acting independently, due to the high sensitivity but limited specificity of the models. While this is a reasonable conclusion, there are still concerns that the high false-positive rate means that each examination will produce several aneurysm candidates requiring review.

Gu et al performed a systematic review and meta-analysis of 19 studies using deep learning models for the detection of cerebral aneurysms.⁷⁸ The authors highlight a lack of high-quality prospective research and acknowledge that because there is a lack of data and description, there are many risks of bias and concerns for applicability. While we agree with this, we consider their quality assessment underestimates these studies' bias and applicability concerns. However, we would caution one of their conclusions that deep learning models can improve clinicians' reading time, based on the analysis of less than a third of their included studies that measure reading time. Furthermore, in studies showing an improved reading time with deep learning models, it has been highlighted by others that caution should be applied.⁷¹ For example, it has been highlighted that first, the reading time is of neither clinical nor statistical significance (3.6 s) and second, that there are concerns regarding study methodology as it is unclear how a reader could review each case with 13.8 false-positives per case in 30s given the number of source images and reformats required (to achieve a sensitivity of 97.5%).

Both systematic reviews also do not encompass machine learning models other than DL. We have found that other machine learning models appear to deliver comparable performance and include one used in a prospective study of 2701 cases performed over 39 months.⁵⁵ The performance accuracy of DL models in particular benefits from large datasets; therefore, one reason for the similarity in performance with other machine learning models may be due to insufficiently sized training datasets. It is noteworthy that the diagnostic accuracy and quality of studies using DL do not appear to be superior to other machine learning models in recent systematic reviews of other AI biomarkers with small datasets.^{66 79}

Another review highlighted studies using AI models for rupture risk stratification and outcome prediction,⁸⁰ which is beyond the scope of the current analysis. Our findings confirm that for aneurysm detection using AI CAD, conclusions are limited due to study bias, and that AI CAD performance is compromised by high false-positive rates.

Implications for future research and clinical practice

AI CAD tools for aneurysm detection are not ready for incorporation into routine clinical practice due to the low level of evidence supporting their use.⁶⁷ Those AI CAD tools that have been evaluated with internal test sets would contribute more to the evidence base if they are re-evaluated in further studies using prospective external data.⁸¹ Further studies where AI CAD tools are trained on a large and representative dataset and evaluated on a prospective multicenter cohort are needed to clinically validate the efficacy of these tools.⁶⁴

CONCLUSION

A range of AI CAD tools designed to automatically detect cerebral aneurysms have been developed and demonstrate promising diagnostic accuracy. However, despite advancements in AI methodology, limited conclusions can be made from the current evidence due to an ongoing high risk of bias and concerns regarding applicability. To ensure clinical adoption, large and representative datasets should be used in studies developing AI CAD tools, with subsequent clinical validation achieved through prospective multicenter studies.

Twitter Thomas C Booth @ThomasCBooth

Acknowledgements We thank all staff supporting the programme of work from (1) the KCL School of Biomedical Engineering & Imaging Sciences in particular, Giusi Manfredi, Vicky Goh, Patrick Wong, Denise Barton, Valentina Vitiello and Sebastien Ourselin, as well as (2) from King's College Hospital NHS Foundation Trust, in particular, Ann-Marie Murtagh, Jasmine Palmer and all others in R & I, and Jonnie Aeron-Thomas.

Contributors MD, SA, MG, DAW, MM, TCB had substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work. MD, SA, MG, DAW, MM, TCB were involved in drafting the work or revising it critically for important intellectual content. MD, SA, MG, DAW, MM, TCB gave final approval of the version to be published. MD and TCB wrote the first draft of the manuscript. SA and TCB determined the concept. MG performed the meta-analysis. MD, SA, MG, DAW, MM, TCB agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. TCB is the guarantor of the study.

Funding This research was funded in whole, or in part, by the Wellcome Trust [WT 203148/Z/16/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Competing interests Microvention Core laboratory for neurointerventional study. Payment to TCB. Not related to Al. Siemens Healthineers Speakers Bureau Educational lecture on brain tumours. Payment to TCB. Not related to aneurysms. Medtronic Speakers Bureau Educational lecture on an independent non-industry sponsored study published in AJNR on Pipeline Flow Diverter device. Payment to TCB. Not related to Al.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data analyzed during the study are available from the corresponding author by request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/ licenses/by/4.0/.

ORCID iD

Thomas C Booth http://orcid.org/0000-0003-0984-3998

REFERENCES

- 1 Jolobe OM. Subarachnoid haemorrhage. Lancet 2007;369:904.
- 2 Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a metaanalysis. Lancet Neurol 2009;8:635-42.
- 3 Vlak MH, Algra A, Brandenburg R, et al. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol 2011;10:626–36.
- 4 Williams LN, Brown RD. Management of unruptured intracranial aneurysms. *Neurology* 2013;3:99–108.
- 5 Yoon NK, McNally S, Taussky P, et al. Imaging of cerebral aneurysms: a clinical perspective. *Neurovasc Imaging* 2016;2:6.
- 6 McDonald RJ, Schwartz KM, Eckel LJ, et al. The effects of changes in utilization and technological advancements of cross-sectional imaging on radiologist workload. Acad Radiol 2015;22:1191-8.

- 7 The Royal College of Radiologists. Clinical radiology workforce census 2019 report, 2020. Available: https://www.rcr.ac.uk/system/files/publication/field_publication_files/ clinical-radiology-uk-workforce-census-2019-report.pdf [Accessed 27 Nov 2020].
- 8 El Naqa I, Haider MA, Giger ML, *et al*. Artificial intelligence: reshaping the practice of radiological sciences in the 21st century. *Br J Radiol* 2020;93:20190855.
- 9 McInnes MDF, Moher D, Thombs BD, *et al.* Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. *JAMA* 2018;319:388–96.
- 10 Bossuyt PM, Leeflang MM. Chapter 6: Developing criteria for including studies. In: *Cochrane handbook for systematic reviews of diagnostic test accuracy version 0.4.* The Cochrane Collaboration, 2008.
- 11 de Vet HCW, Eisinga A, Riphagen II AB. Chapter 7: Searching for studies. In: *Cochrane handbook for systematic reviews of diagnostic test accuracy version 0.4*. The Cochrane Collaboration, 2008.
- 12 Reitsma JB, Rutjes AWS, Whiting P, et al. Assessing methodological quality. In: Deeks JJ, Bossuyt PM, Gatsonis C, eds. Cochrane handbook for systematic reviews of diagnostic test accuracy version 1.0.0. London: The Cochrane Collaboration, 2009.
- 13 Morrison A, Polisena J, Husereau D, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 2012;28:138–44.
- 14 Nussbaumer-Streit B, Klerings I, Dobrescu AI, et al. Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study. J Clin Epidemiol 2020;118:42–54.
- 15 Whiting PF, Rutjes AWS, Westwood ME, *et al.* QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155:529–36.
- 16 Mongan J, Moy L, Kahn CE, Charles E. Checklist for artificial intelligence in medical imaging (CLAIM): a guide for authors and reviewers. *Radiol Artif Intell* 2020;2:e200029.
- 17 Reitsma JB, Glas AS, Rutjes AWS, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982–90.
- 18 Zwinderman AH, Bossuyt PM. We should not pool diagnostic likelihood ratios in systematic reviews. *Stat Med* 2008;27:687–97.
- 19 Borenstein M, Hedges LV, Higgins JPT, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 2010;1:97-111.
- 20 Doebler P. MADA: meta-analysis of diagnostic accuracy. R package version 0.5. 10, 2020. Available: https://cran.r-project.org/web/packages/mada/vignettes/mada.pdf [Accessed 27 Nov 2021].
- 21 Nomura Y, Masutani Y, Miki S, *et al*. Performance improvement in computerized detection of cerebral aneurysms by retraining classifier using feedback data collected in routine reading environment. *J Biomed Graph Comput* 2014;4.
- 22 Jin Z, Arimura H, Kakeda S, et al. An ellipsoid convex enhancement filter for detection of asymptomatic intracranial aneurysm candidates in CAD frameworks. *Med Phys* 2016;43:951–60.
- 23 Arimura H, Li Q, Korogi Y, *et al.* Computerized detection of intracranial aneurysms for three-dimensional MR angiography: feature extraction of small protrusions based on a shape-based difference image technique. *Med Phys* 2006;33:394–401.
- 24 Arimura H, Li Q, Korogi Y, et al. Automated computerized scheme for detection of unruptured intracranial aneurysms in three-dimensional magnetic resonance angiography. Acad Radiol 2004;11:1093–104.
- 25 Joo B, Ahn SS, Yoon PH, et al. A deep learning algorithm may automate intracranial aneurysm detection on MR angiography with high diagnostic performance. Eur Radiol 2020;30:5785-5793.
- 26 Yang X, Blezek DJ, Cheng LTE, *et al*. Computer-aided detection of intracranial aneurysms in MR angiography. *J Digit Imaging* 2011;24:86-95.
- 27 Timmins KM, van der Schaaf IC, Bennink E, et al. Comparing methods of detecting and segmenting unruptured intracranial aneurysms on TOF-MRAS: the ADAM challenge. *Neuroimage* 2021;238:118216.
- 28 Nakao T, Hanaoka S, Nomura Y, et al. Deep neural network-based computer-assisted detection of cerebral aneurysms in MR angiography. J Magn Reson Imaging 2018;47:948-953.
- 29 Hanaoka S, Nomura Y, Takenaga T, et al. HoTPiG: a novel graph-based 3-D image feature set and its applications to computer-assisted detection of cerebral aneurysms and lung nodules. Int J Comput Assist Radiol Surg 2019;14:2095-2107.
- 30 Faron A, Sichtermann T, Teichert N, et al. Performance of adeep-learning neural network to detect intracranial aneurysms from 3D TOF-MRA compared to human readers. *Clin Neuroradiol* 2020;30:591-598.
- 31 Sichtermann T, Faron A, Sijben R, et al. Deep learning-based detection of intracranial aneurysms in 3D TOF-MRA. AJNR Am J Neuroradiol 2019;40:25-32.
- 32 Hou W, Mei S, Gui Q, et al. 1D CNN-based intracranial aneurysms detection in 3D TOF-MRA. Complexity 2020;2020:1–13.
- 33 Allenby MC, Liang ES, Harvey J, et al. Detection of clustered anomalies in single-voxel morphometry as a rapid automated method for identifying intracranial aneurysms. *Comput Med Imaging Graph* 2021;89:101888.
- 34 Stember JN, Chang P, Stember DM, et al. Convolutional neural networks for the detection and measurement of cerebral aneurysms on magnetic resonance angiography. J Digit Imaging 2019;32:808–15.

- 35 Chen G, Wei X, Lei H, *et al*. Automated computer-assisted detection system for cerebral aneurysms in time-of-flight magnetic resonance angiography using fully convolutional network. *Biomed Eng Online* 2020;19:38.
- 36 Ueda D, Yamamoto A, Nishimori M, et al. Deep learning for MR angiography: automated detection of cerebral aneurysms. *Radiology* 2019;290:187–94.
- 37 Nomura Y, Hanaoka S, Nakao T, et al. Performance changes due to differences in training data for cerebral aneurysm detection in head MR angiography images. Jpn J Radiol 2021;39:1039–48.
- 38 Nemoto M, Hayashi N, Hanaoka S, et al. Feasibility study of a generalized framework for developing computer-aided detection systems-a new paradigm. J Digit Imaging 2017;30:629–39.
- 39 Hainc N, Mannil M, Anagnostakou V, et al. Deep learning based detection of intracranial aneurysms on digital subtraction angiography: a feasibility study. *Neuroradiol J* 2020;33:311-317.
- 40 Zeng Y, Liu X, Xiao N, *et al*. Automatic diagnosis based on spatial information fusion feature for intracranial aneurysm. *IEEE Trans Med Imaging* 2020;39:1448-1458.
- 41 Jin H, Geng J, Yin Y, et al. Fully automated intracranial aneurysm detection and segmentation from digital subtraction angiography series using an end-to-end spatiotemporal deep neural network. J Neurointerv Surg 2020;12:1023–7.
- 42 Liu X, Feng J, Wu Z, et al. Deep neural network-based detection and segmentation of intracranial aneurysms on 3D rotational DSA. Interv Neuroradiol 2021;27:648-657.
- 43 Hu T, Yang H, Ni W, et al. Automatic detection of intracranial aneurysms in 3D-DSA based on a Bayesian optimized filter. *Biomed Eng Online* 2020;19:73.
- 44 Duan H, Huang Y, Liu L, et al. Automatic detection on intracranial aneurysm from digital subtraction angiography with cascade convolutional neural networks. *Biomed Eng Online* 2019;18:110.
- 45 Rahmany I, Khlifa N. A priori knowledge integration for the detection of cerebral aneurysm. *Biomed Tech* 2018;63:445–52.
- 46 Rahmany I, Nemmala MEA, Khlifa N, et al. Automatic detection of intracranial aneurysm using LBP and Fourier descriptor in angiographic images. Int J Comput Assist Radiol Surg 2019;14:1353-1364.
- 47 Malik KM, Anjum SM, Soltanian-Zadeh H, et al. A framework for intracranial saccular aneurysm detection and quantification using morphological analysis of cerebral angiograms. *IEEE Access* 2018;6:7970–86.
- 48 Chandra A, Mondal S. Amalgamation of iterative double automated thresholding and morphological filtering: a new proposition in the early detection of cerebral aneurysm. *Multimed Tools Appl* 2017;76:23957–79.
- 49 Khan H, Sharif M, Bibi N. A novel algorithm for the detection of cerebral aneurysm using sub-band morphological operation. *Eur Phys J Plus* 2019;134:1–13.
- 50 Shi Z, Miao C, Schoepf UJ, et al. A clinically applicable deep-learning model for detecting intracranial aneurysm in computed tomography angiography images. Nat Commun 2020;11:6090.
- 51 Shahzad R, Pennig L, Goertz L, et al. Fully automated detection and segmentation of intracranial aneurysms in subarachnoid hemorrhage on CTA using deep learning. Sci Rep 2020;10:21799.
- 52 Dai X, Huang L, Qian Y, *et al.* Deep learning for automated cerebral aneurysm detection on computed tomography images. *Int J Comput Assist Radiol Surg* 2020;15:715-723.
- 53 Hentschke CM, Beuing O, Paukisch H, et al. A system to detect cerebral aneurysms in multimodality angiographic data sets. Med Phys 2014;41:091904.
- 54 Lauric A, Miller E, Frisken S, *et al*. Automated detection of intracranial aneurysms based on parent vessel 3D analysis. *Med Image Anal* 2010;14:149–59.
- 55 Miki S, Hayashi N, Masutani Y, et al. Computer-Assisted detection of cerebral aneurysms in Mr angiography in a routine Image-Reading environment: effects on diagnosis by radiologists. AJNR Am J Neuroradiol 2016;37:1038–43.
- 56 Štepán-Buksakowska IL, Accurso JM, Diehn FE, et al. Computer-aided diagnosis improves detection of small intracranial aneurysms on MRA in a clinical setting. AJNR Am J Neuroradiol 2014;35:1897-902.
- 57 Miki S, Nakao T, Nomura Y, *et al*. Computer-aided detection of cerebral aneurysms with magnetic resonance angiography: usefulness of volume rendering to display lesion candidates. *Jpn J Radiol* 2021;39:652-658.
- 58 Kakeda S, Korogi Y, Arimura H, et al. Diagnostic accuracy and reading time to detect intracranial aneurysms on MR angiography using a computer-aided diagnosis system. AJR Am J Roentgenol 2008;190:459–65.
- 59 Hirai T, Korogi Y, Arimura H, *et al*. Intracranial aneurysms at MR angiography: effect of computer-aided diagnosis on radiologists' detection performance. *Radiology* 2005;237:605-10.
- 60 Sohn B, Park K-Y, Choi J, et al. Deep Learning-Based software improves clinicians' detection sensitivity of aneurysms on brain TOF-MRA. AJNR Am J Neuroradiol 2021;42:1769-1775.
- 61 Park A, Chute C, Rajpurkar P, *et al*. Deep learning-assisted diagnosis of cerebral aneurysms using the HeadXNet model. *JAMA Netw Open* 2019;2:e195600.
- 62 Pennig L, Hoyer UCI, Krauskopf A, *et al*. Deep learning assistance increases the detection sensitivity of radiologists for secondary intracranial aneurysms in subarachnoid hemorrhage. *Neuroradiology* 2021;63:1985-1994.
- 63 Yang J, Xie M, Hu C, et al. Deep learning for detecting cerebral aneurysms with CT angiography. *Radiology* 2021;298:155-163.

- 64 Group F-NBW. BEST (biomarkers, endpoints, and other tools) resource. 1st edn. Bethesda (MD: Food and Drug Administration (US), National Institutes of Health (US), 2016.
- 65 Dean J, Patterson D, Young C. A new golden age in computer architecture: empowering the machine learning revolution. *IEEE Micro* 2018;38:21–9.
- 66 Booth TC, Grzeda M, Chelliah A, *et al.* Imaging biomarkers of glioblastoma treatment response: a systematic review and meta-analysis of recent machine learning studies. *Front Oncol* 2022;12:799662.
- 67 Howick JCI, Glasziou P, Greenhalgh T, et al. Oxford Centre for Evidence-Based Medicine. The Oxford 2011 levels of evidence, 2016.
- 68 Hall MK, Kea B, Wang R. Recognising bias in studies of diagnostic tests Part 1: patient selection. *Emerg Med J* 2019;36:431–4.
- 69 Ramspek CL, Jager KJ, Dekker FW, *et al*. External validation of prognostic models: what, why, how, when and where? *Clin Kidney J* 2021;14:49-58.
- 70 Park SH, Han K. Methodologic guide for evaluating clinical performance and effect of artificial intelligence technology for medical diagnosis and prediction. *Radiology* 2018;286:800–9.
- 71 Kallmes DF, Erickson BJ. Automated aneurysm detection: emerging from the shallow end of the deep learning pool. *Radiology* 2021;298:164–5.
- 72 Hoff T. Deskilling and adaptation among primary care physicians using two work innovations. *Health Care Manage Rev* 2011;36:338-48.
- 73 Lee CS, Nagy PG, Weaver SJ, et al. Cognitive and system factors contributing to diagnostic errors in radiology. AJR Am J Roentgenol 2013;201:611–7.

- 74 Wood DA, Kafiabadi S, Al Busaidi A, et al. Deep learning to automate the labelling of head MRI datasets for computer vision applications. *Eur Radiol* 2022;32:725–36.
- 75 Wood D, Kafiabadi S, Al Busaidi A. Labelling imaging datasets on the basis of Neuroradiology reports: a validation study. *Interpretable and Annotation-Efficient Learning for Medical Image Computing* 2020:254–65.
- 76 Alwalid O, Long X, Xie M, et al. Artificial intelligence applications in intracranial aneurysm: achievements, challenges and opportunities. Acad Radiol 2022;29 Suppl 3:S201-S214.
- 77 Abdollahifard S, Farrokhi A, Kheshti F, et al. Application of convolutional network models in detection of intracranial aneurysms: a systematic review and meta-analysis. Interv Neuroradiol 2022:15910199221097475.
- 78 Gu F, Wu X, Wu W, et al. Performance of deep learning in the detection of intracranial aneurysm: a systematic review and meta-analysis. Eur J Radiol 2022;155:110457.
- 79 Booth TC, Williams M, Luis A, et al. Machine learning and glioma imaging biomarkers. Clin Radiol 2020;75:20–32.
- 80 Shi Z, Hu B, Schoepf UJ, et al. Artificial intelligence in the management of intracranial aneurysms: current status and future perspectives. AJNR Am J Neuroradiol 2020;41:373-379.
- 81 Korevaar DA, Hooft L, Askie LM, et al. Facilitating prospective registration of diagnostic accuracy studies: a STARD initiative. *Clin Chem* 2017;63:1331-1341.